Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

409 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Role of Normalized T-Cell Subsets in Predicting Comorbidities in a Large Cohort of Geriatric HIV-Infected Patients.
Calcagno A, Piconi S, Focà E, Nozza S, Carli F, Montrucchio C, Cattelan AM, Orofino G, Celesia BM, Morena V, De Socio GV, Guaraldi G; GEPPO (GEriatric Patients living with HIV/AIDS: a Prospective Multidimensional cOhort) Study Group. Calcagno A, et al. J Acquir Immune Defic Syndr. 2017 Nov 1;76(3):338-342. doi: 10.1097/QAI.0000000000001496. J Acquir Immune Defic Syndr. 2017. PMID: 28708810
Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism.
Siccardi M, D'Avolio A, Nozza S, Simiele M, Baietto L, Stefani FR, Moss D, Kwan WS, Castagna A, Lazzarin A, Calcagno A, Bonora S, Back D, Di Perri G, Owen A. Siccardi M, et al. Among authors: calcagno a. Pharmacogenet Genomics. 2010 Dec;20(12):759-65. doi: 10.1097/FPC.0b013e3283402efb. Pharmacogenet Genomics. 2010. PMID: 21217360 Clinical Trial.
Short-term additional enfuvirtide therapy is associated with a greater immunological recovery in HIV very late presenters: a controlled pilot study.
Bonora S, Calcagno A, Cometto C, Fontana S, Aguilar D, D'Avolio A, Gonzalez de Requena D, Maiello A, Dal Conte I, Lucchini A, Di Perri G. Bonora S, et al. Among authors: calcagno a. Infection. 2012 Feb;40(1):69-75. doi: 10.1007/s15010-011-0223-4. Epub 2011 Dec 2. Infection. 2012. PMID: 22135137 Clinical Trial.
The Less Drugs Regimens (LDRs) therapy approach in HIV-1: an Italian expert panel perspective for the long-term management of HIV-1 infection.
Scientific Coordination Committee; Marcotullio S, Andreoni M, Antinori A, d'Arminio Monforte A, Di Perri G, Galli M, Ippolito G, Perno CF, Rizzardini G, Lazzarin A; Rapporteur Committee; Cinque P, Fares G, Foglia E, Gervasoni C, Murri R, Nozza S, Rusconi S. Scientific Coordination Committee, et al. New Microbiol. 2012 Jul;35(3):259-77. Epub 2012 Jun 30. New Microbiol. 2012. PMID: 22842596 Free article. No abstract available.
Tenofovir plasma concentrations according to companion drugs: a cross-sectional study of HIV-positive patients with normal renal function.
Calcagno A, Gonzalez de Requena D, Simiele M, D'Avolio A, Tettoni MC, Salassa B, Orofino G, Bramato C, Libanore V, Motta I, Bigliano P, Orsucci E, Di Perri G, Bonora S. Calcagno A, et al. Antimicrob Agents Chemother. 2013 Apr;57(4):1840-3. doi: 10.1128/AAC.02434-12. Epub 2013 Feb 4. Antimicrob Agents Chemother. 2013. PMID: 23380733 Free PMC article.
Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection.
Nozza S, Bigoloni A, Calcagno A, Galli L, Pignataro AR, D'Avolio A, Carbone A, Ripa M, Bonora S, Lazzarin A, Castagna A. Nozza S, et al. Among authors: calcagno a. J Antimicrob Chemother. 2014 May;69(5):1436-9. doi: 10.1093/jac/dkt530. Epub 2014 Jan 23. J Antimicrob Chemother. 2014. PMID: 24458511 No abstract available.
409 results